The adoptive transfer of CAR-T cells against CD19 was effective in treating relapsed and refractory acute lymphoblastic leukemia (ALL) with complete remission rates of up to 90% [244]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.